Community hub
Recent from talks
Knowledge base stats:
Talk channels stats:
Members stats:
GoodRx
GoodRx Holdings, Inc., is an American healthcare company that operates a telemedicine platform and free-to-use website and mobile app that track prescription drug prices in the United States and provide drug coupons for discounts on medications. GoodRx checks drug prices at more than seventy-five thousand pharmacies in the United States. The platform allows individuals to consult with a doctor online and obtain a prescription for certain types of medications at a cost of US$20, regardless of insurance status. Medical testing services, which vary in price, are also offered through the platform.
In 2017, the website received about fourteen million visitors a month. As of February 25, 2020, "millions of people" had downloaded the GoodRx app.
GoodRx was founded in Santa Monica, California, in 2011. GoodRx experienced substantial growth in net income in 2017 ($9 million), 2018 ($44 million) and 2019 ($66 million) while a loss of $293.6 million in 2020 due to IPO-related expenses. During these years it expanded its services to include telehealth, and became a publicly traded company.
GoodRx generated $745.4 million in revenue for the full year 2021, a 35.36% increase over 2020. GoodRx's stock price trended downward during the first half of 2021, with shares falling 10.7%. It has been attributed to Amazon's entry into the online pharmacy market and a significant deceleration in GoodRx's user growth.
GoodRx reported full-year revenue of $766.6 million, with adjusted EBITDA reaching $213.5 million, exceeding guidance in the fourth quarter. GoodRx reported that 41% of prescriptions filled using its coupons were newly adherent, meaning they would not have been filled without the service.
GoodRx reported a full-year 2023 revenue of $750.3 million, a decrease of 2.1% from 2022. However, its fourth-quarter revenue increased by 7% year-over-year, showing a positive shift in its financial trajectory. GoodRx achieved an Adjusted EBITDA of $217.4 million for the year and an Adjusted EBITDA Margin of 28.6%.
In 2024, GoodRx achieved 6% revenue growth with $792.3 million for the full year and turned a net loss into a positive net income of $16.4 million. The company also demonstrated strong operational efficiency, with a 32.8% increase in full-year Adjusted EBITDA.
In Q2 2025, GoodRx reported revenue of $203.1 million, a 1.2% increase from the previous year, and a net income of $12.8 million, a significant 92% jump, which resulted in a 6.3% net income margin. However, prescription transaction revenue declined by 3% due to a decrease in monthly active consumers, but this was offset by strong 32% growth in its Pharma Manufacturer Solutions business. GoodRx also saw a 7% decrease in subscription revenue.
Hub AI
GoodRx AI simulator
(@GoodRx_simulator)
GoodRx
GoodRx Holdings, Inc., is an American healthcare company that operates a telemedicine platform and free-to-use website and mobile app that track prescription drug prices in the United States and provide drug coupons for discounts on medications. GoodRx checks drug prices at more than seventy-five thousand pharmacies in the United States. The platform allows individuals to consult with a doctor online and obtain a prescription for certain types of medications at a cost of US$20, regardless of insurance status. Medical testing services, which vary in price, are also offered through the platform.
In 2017, the website received about fourteen million visitors a month. As of February 25, 2020, "millions of people" had downloaded the GoodRx app.
GoodRx was founded in Santa Monica, California, in 2011. GoodRx experienced substantial growth in net income in 2017 ($9 million), 2018 ($44 million) and 2019 ($66 million) while a loss of $293.6 million in 2020 due to IPO-related expenses. During these years it expanded its services to include telehealth, and became a publicly traded company.
GoodRx generated $745.4 million in revenue for the full year 2021, a 35.36% increase over 2020. GoodRx's stock price trended downward during the first half of 2021, with shares falling 10.7%. It has been attributed to Amazon's entry into the online pharmacy market and a significant deceleration in GoodRx's user growth.
GoodRx reported full-year revenue of $766.6 million, with adjusted EBITDA reaching $213.5 million, exceeding guidance in the fourth quarter. GoodRx reported that 41% of prescriptions filled using its coupons were newly adherent, meaning they would not have been filled without the service.
GoodRx reported a full-year 2023 revenue of $750.3 million, a decrease of 2.1% from 2022. However, its fourth-quarter revenue increased by 7% year-over-year, showing a positive shift in its financial trajectory. GoodRx achieved an Adjusted EBITDA of $217.4 million for the year and an Adjusted EBITDA Margin of 28.6%.
In 2024, GoodRx achieved 6% revenue growth with $792.3 million for the full year and turned a net loss into a positive net income of $16.4 million. The company also demonstrated strong operational efficiency, with a 32.8% increase in full-year Adjusted EBITDA.
In Q2 2025, GoodRx reported revenue of $203.1 million, a 1.2% increase from the previous year, and a net income of $12.8 million, a significant 92% jump, which resulted in a 6.3% net income margin. However, prescription transaction revenue declined by 3% due to a decrease in monthly active consumers, but this was offset by strong 32% growth in its Pharma Manufacturer Solutions business. GoodRx also saw a 7% decrease in subscription revenue.